NYSE:PRX - Par Pharmaceutical Companies Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Par Pharmaceutical Companies (NYSE:PRX)

Par Pharmaceutical Companies logoPar Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Receive PRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Par Pharmaceutical Companies (NYSE:PRX) Frequently Asked Questions

What is Par Pharmaceutical Companies' stock symbol?

Par Pharmaceutical Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRX."

Who are Par Pharmaceutical Companies' key executives?

Par Pharmaceutical Companies' management team includes the folowing people:
  • Paul V. Campanelli, Chief Executive Officer (Age 54)
  • Michael A. Tropiano, Chief Financial Officer, Executive Vice President (Age 57)
  • Terrance John Coughlin, Chief Operating Officer (Age 52)
  • Thomas J. Haughey, Chief Administrative Officer, General Counsel (Age 51)

Has Par Pharmaceutical Companies been receiving favorable news coverage?

News headlines about PRX stock have trended positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Par Pharmaceutical Companies earned a news impact score of 0.27 on Accern's scale. They also assigned press coverage about the healthcare company an impact score of 46.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Par Pharmaceutical Companies?

Shares of PRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Par Pharmaceutical Companies?

Par Pharmaceutical Companies' mailing address is 1 Ram Ridge Rd, CHESTNUT RIDGE, NY 10977-6714, United States. The healthcare company can be reached via phone at +1-845-5735500.

MarketBeat Community Rating for Par Pharmaceutical Companies (PRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Par Pharmaceutical Companies and other stocks. Vote "Outperform" if you believe PRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Par Pharmaceutical Companies (NYSE:PRX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/26/2016 forward)


Par Pharmaceutical Companies (NYSE:PRX) Earnings History and Estimates Chart

Earnings by Quarter for Par Pharmaceutical Companies (NYSE:PRX)

Par Pharmaceutical Companies (NYSE PRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2012$1.10$1.62ViewN/AView Earnings Details
5/8/2012$0.72$0.80ViewN/AView Earnings Details
2/28/2012$0.74$0.78ViewN/AView Earnings Details
11/2/2011$0.73$0.74ViewN/AView Earnings Details
8/3/2011$0.74$0.84ViewN/AView Earnings Details
5/5/2011$0.89$0.96ViewN/AView Earnings Details
2/24/2011$0.67$0.61ViewN/AView Earnings Details
11/3/2010Q3 2010$0.54$0.86ViewN/AView Earnings Details
8/4/2010Q2 2010$0.58$0.71ViewN/AView Earnings Details
5/4/2010Q1 2010$0.66$0.67ViewN/AView Earnings Details
2/24/2010Q4 2009$0.57$0.65ViewN/AView Earnings Details
11/6/2009Q3 2009$0.49$0.77ViewN/AView Earnings Details
8/4/2009Q2 2009$0.48$0.65ViewN/AView Earnings Details
5/6/2009Q1 2009$0.27$0.49ViewN/AView Earnings Details
11/6/2008Q3 2008$0.09$0.26ViewN/AView Earnings Details
8/7/2008Q2 2008$0.14($0.59)ViewN/AView Earnings Details
5/8/2008Q1 2008$0.15$0.17ViewN/AView Earnings Details
2/29/2008Q4 2007$0.13$0.19ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Par Pharmaceutical Companies (NYSE:PRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Par Pharmaceutical Companies (NYSE PRX) Insider Trading and Institutional Ownership History

Insider Trading History for Par Pharmaceutical Companies (NYSE:PRX)

Par Pharmaceutical Companies (NYSE PRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Par Pharmaceutical Companies (NYSE PRX) News Headlines


SEC Filings

Par Pharmaceutical Companies (NYSE:PRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Par Pharmaceutical Companies (NYSE:PRX) Income Statement, Balance Sheet and Cash Flow Statement


Par Pharmaceutical Companies (NYSE PRX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.